Free BRCA testing scheme opens for eligible patients
Bastillepost · 3 SOURCESabout 10 hours ago5 MIN

Summary
A new “BRCA Genetic Testing Subsidy Programme” has opened for applications, offering free BRCA1/2 testing to eligible breast cancer and prostate cancer patients in Hong Kong and Macau. The programme is jointly launched by the Cancer Information Network Charity Foundation, Inocras Hong Kong and AstraZeneca Hong Kong, with organisers saying the aim is to support more precise treatment planning and family risk assessment. It covers patients with HR-positive/HER2-negative breast cancer, triple-negative breast cancer and metastatic prostate cancer. The subsidy also includes professional genetic counselling services, with each patient allowed to use the programme once and places available on a first-come, first-served basis
Key Points
- The scheme began accepting applications on November 19 and is open to eligible patients in Hong Kong and Macau.
- Organisers said a similar programme run in 2024 and 2025 benefited 922 patients, with 127 successfully matched to suitable targeted drugs
- Clinical oncologist Lo Wing-sim (盧頴嬋) said BRCA genes normally suppress tumour growth, but mutations can sharply raise cancer risk.
- Women carrying BRCA1 or BRCA2 mutations face breast cancer risks by age 70 of 55% to 65% and 45% respectively.
- Men with relevant BRCA mutations face a prostate cancer risk 4.5 times higher than that of the general male population.
Why It Matters
For patients, the programme may reduce the cost barrier to genetic testing while helping doctors decide whether treatments such as PARP inhibitors are suitable. For families with a history of breast, ovarian or prostate cancer, the testing may also prompt earlier screening and monitoring because first-degree relatives can have a 50% chance of inheriting the same mutation.